Background: HDL-associated paraoxonase 1 (PON1) activity is associated with cardiovascular
Introduction
Paraoxonase 1 (PON1) is a glycoprotein enzyme physically associated with high-density lipoprotein (HDL). PON1 is partially responsible for the cardioprotective effects of HDL through inhibition of low-density lipoprotein (LDL) peroxidation (1, 2) and inhibition of macrophage-endothelium interactions (2, 3) , both of which are underlying changes in atherogenesis. Knockout studies in mice have demonstrated that a lack of PON1 enzyme activity leads to increased susceptibility to organophosphate toxicity and cardiovascular disease (CVD)(4), likely due to an inability to neutralize oxidized LDL (5) . In light of the recent failures in clinical trials (6) and Mendelian randomization analyses (7, 8) to demonstrate a causal relationship between plasma HDL (HDL-C) and CVD, there is an increased emphasis on understanding the multiple biologic dimensions of HDL, such as PON1, that may be cardioprotective but are not reflected by measures of HDL-C.
PON1 has broad substrate specificity and metabolizes toxic organophosphorus insecticides (9) .
For biological purposes, PON1 activity is generally measured with regard to the rate of hydrolysis of paraoxon, diazoxon, and phenylacetate (arylesterase activity) (10, 11) . These are termed POase, DZOase, and AREase activities, respectively. AREase enzymatic activity is less unaffected by the functional PON1 Q192R polymorphism, thus making it the best reflection of the levels of PON1 protein (12) . PON1 enzyme activity is influenced by both genetic and environmental factors. There are four well established functional PON1 mutations (13) : two missense mutations (PON1 Q192R [rs662] and PON1 L55M [rs854560]) and two 5' regulatory (PON1 -108C/T [rs705379] and PON1 -162A/G by guest, on October 14, 2017 www.jlr.org
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[rs705381]). PON1 -108C/T has the largest effect on AREase activity, altering expression likely due to modification of an Sp1 binding site (14, 15) . Recent findings within this Carotid Lesion Epidemiology and Risk (CLEAR) cohort attribute approximately 21% of PON1 AREase activity to these four functional PON1 mutations and six additional common variants within the PON gene cluster (including those in PON2 and PON3) (16) . Rare deleterious variants have also been identified (17) . In addition, we reported that dietary cholesterol, alcohol, and vitamin C were all positively predictive of PON1 activity, while dietary iron and folic acid predicted reduced PON1 activity in 1,402 subjects from the CLEAR cohort (18) ; these factors accounted for an additional 8.2% of PON1 activity when adjusting for age, sex, and current smoking status.
Despite these findings, a large portion of PON1 activity variance remains unexplained. This may be due to genetic variation either at other loci or due to rare single nucleotide variants (SNVs) in PON1. While rare SNVs are well known as causative mutations in Mendelian traits, they are only beginning to be studied in large datasets considering complex diseases or in quantitative phenotypes. Rare SNVs are expected to account for some of the "missing heritability" of traits such as PON1 activity (19) (20) (21) (22) . Moreover, rare coding SNVs often affect protein function, as compared to noncoding regulatory variants that affect the levels of protein. Accordingly, we used a two-step process to determine if common or rare SNVs at other loci contribute to variation in paraoxonase activity. We first considered the associations from the relatively common SNPs on the Illumina HumanCVD BeadChip, and then selected genes nominated by this analysis to consider the effects of rare SNVs typed utilizing the new Illumina HumanExome
BeadChip. This was done to limit the number of hypotheses tested and maximize power. We also catalogued the 92 non-synonymous and 5' and 3 '- 
PON1 phenotyping
The PON1 AREase activity was measured by a continuous spectrophotometric assay as previously described (28) . AREase activity was measured in triplicate and averaged. AREase activity was utilized as the primary measured outcome of PON gene cluster variation due to its closer correlation with protein levels than hydrolysis rates of the toxic substrates paraoxon or diazoxon.
Common variant analysis
Regression analyses of common variants genotyped on the CVD chip were performed using the PLINK analysis package (31 Because SKAT is a regional DNA window-based test of association and we wanted to limit our tests, we chose to perform analyses on candidate genes (described in Table 2 ) identified by common variant analyses and with a false discovery rate (FDR) < 0.10 (PON1, FTO, ITGAL, and SERPINA12). For these gene regions found to not be significant for association with PON1
AREase activity, a second SKAT analysis was performed using adjusted weights that give higher weights to rare variants (32) . In order to determine if the rare variant associations were independent of the common variant associations in the same genes, a separate sensitivity analysis was performed in 933 subjects with both Exome and CVD chip genotypes, with the SKAT analysis model adjusted for the common variants in addition to the other covariates.
In addition, we performed a secondary analysis considering the entire PON gene cluster (PON1, PON2, and PON3), as variants in PON2 and PON3 have been previously identified to be predictive of PON1 AREase activity in this cohort (26 
Results

Common Variant Association with PON1 AREase activity
Demographic measures of the CLEAR cohort are presented in Table 1 . A total of 1,362 subjects had complete CVD chip genotype, covariate, and phenotype data for analyses of common variant association with PON1 AREase activity. The average age was 67.8 years, the subjects were 86.7% male, 18.2% current smokers, and 39.4% statin users. Of the 1,362 subjects, 460 (33.8%)
were CAAD cases with >80% stenosis in one or both internal carotid arteries or were postcarotid endarterectomy, 687 (50.5%) were controls with <15% stenosis in both carotid arteries, 166 (12.2%) had moderate internal carotid obstruction with 50-79% stenosis, 27 (2.0%) had mild carotid obstruction with 15-49% stenosis, and 21 (1.5%) were ascertained for lower extremity peripheral vascular disease (ankle-brachial index of < 0.9).
Linear regression analyses across the 33,057 SNPs genotyped by the Illumina HumanCVD BeadChip in 1,362 subjects adjusting for age, sex, current smoking status, and the four functional PON1 mutations resulted in the detection of one additional PON1 SNP (rs2237583, p=3.88x10 -8 )
reaching genome-wide significance (<5x10 -8 ) for association with PON1 AREase activity (see Table 2 ). An additional 12 SNPs spanning seven different genes (PON1, FTO, SERPINA12, ITGAL, ALOX12, PDE4D, and FAM178A) were associated with PON1 AREase at the level of suggestive significance (p<10 -4 ). As there were multiple SNPs located within PON1 and FTO, we evaluated the linkage disequilibrium (LD) between those SNPs in the CLEAR cohort data.
For PON1, the three SNPs (rs2237583, rs3917478, and rs2299262) associating with PON1
AREase activity were in LD of r were all in strong pairwise LD.
Exome Chip Analysis
SKAT analyses of the Exome chip data considered an overlapping group of subjects (n=933 with both CVD and Exome chip data). The Exome chip genotyping was performed preferentially on CAAD cases (70%, see Table 1 ). The average age was 69.6 years, and these subjects were 89.8% male, 14.9% current smokers, and 52.5% statin users. The mean PON1 AREase activity was 135.39 IU, nearly identical to that of the CVD chip subjects.
Using a FDR of < 0.1 or p < 2.5 x 10 -5 , four candidate genes were carried forward to rare variant testing SKAT analysis: PON1, FTO, ITGAL, and SERPINA12. These Exome chip data contained seven, four, four, and 10 polymorphic SNVs for PON1, FTO, ITGAL, and SERPINA12, respectively (see Table 3 ). We utilized SKAT to look for associations between each of these four groups of SNVs and PON1 AREase activity, adjusting for age, sex, current smoking status, and the genotypes of PON1 Q192R , PON1 L55M , PON1 -108C/T and PON1 -162A/G .
The PON1 region SNVs were highly predictive (p = 2.24 x 10 -4 ) of PON1 activity, while FTO (p = 0.019) and SERPINA12 (p = 0.0391) SNVs were more weakly associated with PON1 activity ( Table 3 ). The ITGAL gene region SNVs were not associated with PON1 AREase activity using default weights in SKAT (p = 0.169); however, when using a weighting algorithm that gave To test whether the rare variant association results were independent of the common SNP associations detected in the CVD chip analysis, we ran a secondary analysis in the overlapping subjects with both CVD and Exome chip genotypes (n=933), adjusting the SKAT model for the genotypes of SNPs from the common variant analysis with FDR < 0.10 (see Table 2 ) in addition to age, sex, current smoking status, and the four functional PON1 genotypes. From this analysis, adjusting for common variants, PON1 (p = 3.42 x 10 -3 ) and FTO (p = 9.52 x 10 -3 ) SNVs remained significant for association with adjusted PON1 AREase activity. SERPINA12 became marginally significant (p = 0.09) when adjusting for common SERPINA12 variants previously identified in this cohort. When adjusting for its common variants, ITGAL SNVs remained significant for association with PON1 activity using adjusted weights (p = 9.88 x 10 -4 ).
Prior research in a male-only subset of this cohort identified SNPs in PON2 and PON3 that predicted of PON1 activity (26) . Thus, we performed a secondary SKAT analysis of the entire PON gene cluster (PON1, PON2, PON3) on chromosome 7. In total, there were 13 polymorphic SNVs within the region represented in our cohort, including the seven PON1 SNVs previously analyzed by SKAT (see Table 3 ). When testing for association with PON1 AREase in a SKAT Prior work in the CLEAR cohort identified six additional SNPs in the PON gene cluster (26) (four in PON1 and one each in PON2 and PON3), excluding the four commonly recognized functional SNPs, which were predictive of PON1 activity. We therefore performed a separate SKAT analysis of PON1 and the PON gene cluster SNV associations with PON1 AREase activity to insure that our results were not due to LD with these previously identified common variants. In this SKAT model, the model included the covariates of the genotypes of these six previously identified SNPs (rs854567, rs2299257, rs223783, rs2375005, rs3917486, and rs11768074), as well as the four functional PON1 mutations, age, sex, and current smoking status. We found that the p-values for both PON1 (1.92 x 10 -3 ) and the PON gene cluster (9.30 x 10 -3 ) were less significant when adjusting for these variants, though still highly predictive of PON1 activity. Only PON1 SNV rs3917503 from the Exome chip data was in LD of r 2 > 0.60 with one of the six previously identified common variants, rs2299257 (r 2 = 0.74). These results suggest that, except for rs2299257, the SNVs reported to be associated with PON1 activity here are independent of previously reported common variants. (51), among other disorders (52) . Given the recent failures of HDL-C to prevent atherosclerotic outcomes in recent trials and the varied effects of PON1 on numerous important human diseases, a fuller understanding of PON1 activity may shed light on the cardioprotective role of HDL. To this end, we have expanded the search for genetic variation that predicts PON1 activity to loci outside of the PON1 coding region and to rare variants.
Description of the PON gene cluster SNVs in the ESP6500 data
In this study, we report novel findings that common variants in FTO, ITGAL and SERPINA12 predict PON1 activity. In addition, we find that rare SNVs within the PON gene cluster are predictive of PON1 AREase activity. For FTO, ITGAL and PON1 there were significant effects of rare SNVs on PON1 activity that were independent of the effects of the common variants, while for SERPINA12 the independent effects of the rare variants were marginal (p=0.09).
Variation in FTO, ITGAL and SERPINA12 has not previously been explored for effects on PON1 (59, 62) . However, when testing all SERPINA12 variants present in our data, we did not find a significant association with either BMI or diabetes (data not shown). Interestingly, PON1 activity has long been known to be lower in those with diabetes(51) and PON1 has also been reported as an anti-diabetic enzyme that stimulates insulin release from pancreatic beta cells (63) . However, SNPs within PON1 have not been found to predict diabetes (64) . The SERPINA12 SNP rs7152296 minor allele was associated with a decrease in PON1 AREase (beta coefficient = -4.8); in contrast, all FTO SNP minor alleles identified were positively associated with PON1 activity. Further functional studies will be required to determine both the relationships of FTO and SERPINA12 to paraoxonase biology; these results suggest that the relationship of PON1 activity to diabetes may be driven by loci is associated with reduced PON1 activity (18) . One could speculate that the inhibitory effect of iron may be through increased 12-LO. We observe that the SNPs in ALOX12 and PDE4D, and nearby FAM178A, are among those with the largest effect size, but the smallest minor allele frequencies. Thus, it is possible that these represent true positives that we are underpowered to detect a significant association for due to low minor allele frequency. Further investigation of these loci, especially of ALOX12, due to its biology, is suggested by our findings.
Utilizing SKAT to analyze both the rare and common variants represented on the Illumina Exome chip, we were able to detect significant associations for PON1, PON3, or the PON gene cluster as a whole, even when known functional SNPs were considered as covariates. PON3 is also an HDL-associated enzyme, but is expressed in much lower levels than PON1 (75) . In contrast to both PON1 and PON3, PON2 is ubiquitously expressed (76) . Given that SNPs in PON2 have been previously reported in this cohort to predict PON1 enzyme activity, the failure of additional PON2 SNPs to predict PON1 activity in SKAT analyses may reflect a lack of rare SNVs in this sample, as only 2 PON2 SNPs from the Exome chip were polymorphic in the CLEAR cohort; these two SNVs, rs7493 and rs12026, were common and in tight LD (MAF of 24.6% for both and r 2 = 1.0).
When adjusting for PON gene cluster variants that have been previously associated with PON1 activity(26), the p-values for association of the previously unidentified variants remained significant, but not as strongly associated with PON1 AREase for both PON1 and the PON gene The common variant analyses were performed with the Illumina HumanCVD BeadChip, which was selective for genes that were potentially involved in cardiovascular phenotypes. The CVD chip, and thus this study, could have excluded consideration of loci relevant to PON1 biology.
Finally, while replication in an independent sample is ideal, given the need for larger datasets to identify rare variant effects, we considered all available data, rather than stratifying to provide a replication set. Cohorts in which PON1 activity can be measured are limited due to the fact that PON1 activity is calcium dependent and, thus, cannot be measured from plasma stored in EDTA tubes due to calcium chelation and irreversible inactivation of PON1. Therefore, replication data were not available. However, our finding of independent effects of both common and pooled rare variants in the same loci for the same trait provides some validation of the associations of variation at these loci and PON1 activity.
In conclusion, we describe the novel findings that common and rare genetic variants in FTO, ITGAL and SERPINA12 are associated with PON1 enzyme activity. Additionally, an association with ALOX12 variants does not meet our experiment-wide cut-off, but suggests the need for further study. These associations strengthen the tie of PON1 activity to diabetes and by guest, on October 14, 2017 www.jlr.org
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inflammation. We also identify rare variants in these loci and the PON1 gene cluster that predict PON1 activity. In addition, we describe 92 non-synonymous, 5'-and 3'-noncoding variants from the ESP6500 data for the PON gene cluster. Given the importance of PON1 to HDL biology and human disease and the potential for rare variants to explain a large portion of the "missing heritability" of complex genetic traits, future studies will be needed to further elucidate the genetic determinants of PON1 enzymatic activity and their relationship to cardiovascular disease risk, including BMI and inflammation. 
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